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EFFECTIVENESS OF THROMBOLYSIS WITH
INTRAVENOUS ALTEPLASE FOR ACUTE
ISCHEMIC STROKE IN OLDER ADULTS
To the Editor: Thrombolysis with intravenous alteplase is
widely accepted as an effective treatment for individuals
with acute ischemic stroke,1 but few individuals aged 80
and older are treated with alteplase.2 The risk:benefit ratio
of thrombolysis might be less favorable with older age
because of a higher risk of adverse events and lower
efficacy.3,4 Outcomes in older adults treated with alteplase
has been studied mostly in comparison with younger indi-
viduals,4,5 but to reach a firm conclusion concerning the
appropriateness of treating older adults with thrombolysis,
one should also contrast treatment with no treatment. Indi-
viduals aged 80 and older with stroke have a higher case-
fatality rate, longer hospitalization, and are less likely to be
discharged home than younger individuals.6 The results of a
recent collaborative project suggest that individuals aged 80
and older derive similar benefit from treatment with intra-
venous alteplase as younger individuals.7 The aim of the
present study was to assess the effectiveness of thrombolysis
in relation to age in an unselected prospective observational
cohort, in which all individuals with an ischemic stroke
admitted within 4 hours of symptom onset were registered.
PARTICIPANTS AND METHODS
During a 2-year period from 2005 to 2007, all individuals
aged 18 and older with acute ischemic stroke admitted
within 4 hours of symptom onset were registered in 12 hos-
pitals in the Netherlands. Participant data included demo-
graphics and baseline characteristics. All participants were
followed up at 3 months after hospitalization by telephone,
which they had consented to. A good outcome at 3 months
was defined as a score on the modified Rankin Scale of 2
or less. The safety endpoints were death and symptomatic
intracranial bleeding (sICH), defined as a hemorrhage con-
firmed using computed tomography scan and leading to a
greater deficit on the National Institutes of Health Stroke
Scale (NIHSS) than at baseline. A multivariable logistic
regression model with adjustment for prognostic variables
(age, sex, systolic blood pressure, NIHSS score at admis-
sion, diabetes mellitus, atrial fibrillation, history of previ-
ous stroke, and heart failure) was used to assess the
effectiveness of thrombolysis according to age category.
RESULTS
Overall, 1,657 individuals were registered, of whom 446
were aged 80 and older and 1,211 were younger than 80.
Table 1 shows baseline characteristics, stroke severity, and
outcome. The adjusted odds ratio (aOR) for good outcome
was 1.19 (95% confidence interval (CI) = 0.71–1.98) in
the older age category and 1.48 (95% CI = 1.08–2.04) in
the younger age category. Heterogeneity between age
strata was tested for by computing the Mantel-Haenszel
ORs (MH-ORs) according to treatment, adjusted for
NIHSS score at admission. The overall MH-OR for good
outcome was 1.54 (95% CI = 1.18–2.01). There was no
Table 1. Baseline Participant Characteristics and Outcomes According to Treatment and Age Group
Characteristic and Outcome
 80 <80
No Thrombolysis,
n = 283
Thrombolysis,
n = 163
No Thrombolysis,
n = 678
Thrombolysis,
n = 533
Characteristic
Age, mean ± SD 85 ± 4 85 ± 4 66 ± 11 64 ± 12
Male, n (%) 120 (42) 70 (43) 400 (59) 312 (59)
Onset to needle time, minutes, mean ± SD – 141 ± 34 – 137 [41]
National Institutes of Health Stroke Scale score,
mean ± SD
8 ± 8 11 ± 7 5 ± 6 10 ± 6
Prior stroke or transient ischemic attack, n (%) 64 (23) 31 (19) 158 (23) 78 (15)
Myocardial infarction, n (%) 45 (16) 22 (14) 94 (14) 66 (13)
Peripheral artery disease, n (%) 39 (14) 14 (9) 65 (10) 40 (8)
Heart failure, n (%) 35 (12) 22 (14) 44 (7) 31 (6)
Hypertension, n (%) 153 (54) 80 (49) 356 (53) 257 (48)
Atrial fibrillation, n (%) 96 (34) 44 (27) 99 (15) 57 (11)
Diabetes mellitus, n (%) 52 (18) 23 (14) 131 (19) 68 (13)
Hypercholesterolemia, n (%) 86 (31) 31 (19) 305 (45) 216 (41)
Systolic blood pressure, mmHg, mean ± SD 168 ± 30 162 ± 29 162 ± 32 158 ± 26
Diastolic blood pressure, mmHg, mean ± SD 82 ± 19 81 ± 17 86 ± 17 84 ± 15
Outcome
Good outcome (modified Rankin Scale score  2),
n (%)
96 (35) 46 (29) 441 (68) 287 (57)
Fully adjusted odds ratio for good outcome
(95% confidence interval)*
1.19 (0.71–1.98) 1.48 (1.08–2.04)
Symptomatic intracranial bleeding
complication, n (%)
– 12 (7.4) – 24 (4.5)
100% is the total participants registered within one age category per treatment arm.
*Multiple logistic regression model, including age, sex, atrial fibrillation, diabetes mellitus, previous stroke, and blood pressure at admission.
SD = standard deviation.
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evidence of heterogeneity of ORs between the age catego-
ries (test of homogeneity of ORs, P = .39). Participants
aged 80 and older with stroke had a higher case-fatality
rate and a higher rate of sICH than younger patients when
treated with thrombolysis (7.4% vs 4.5%; relative
risk = 1.51, 95% CI = 0.77–2.97).
DISCUSSION
This retrospective analysis of unselected individuals sug-
gests that thrombolysis for acute ischemic stroke leads to
better outcomes than lack of treatment with alteplase in
individuals aged 80 and older as well. These results confirm
the observations in the Safe Implementation of Treatment
in Stroke—International Stroke Thrombolysis Registry
(SITS-ISTR). This is the largest prospective observational
study of outcomes of thrombolysis in individuals aged 80
and older, with 21,242 participants, of whom 1,831 were
aged 80 and older. The main finding in SITS-ISTR was that
the overall rate of symptomatic and asymptomatic ICH
was not greater in those aged 80 and older.8 The compari-
son of these data with those from matched historical con-
trols showed that older age is associated with poorer
outcomes, but the association between thrombolysis treat-
ment and better outcomes is maintained in very elderly
people.7 The SITS-MOST registry is an uncontrolled study
and a voluntary registry, so consecutive inclusion and
absence of selection is difficult to guarantee.9 The Third
International Stroke trial will provide stronger evidence;
this randomized controlled trial seeks to determine whether
a wider range of individuals may benefit from alteplase,
including patients aged 80 and older.10 Additional evidence
of a beneficial effect of thrombolysis is presented here
because the stratified analysis shows a significant overall
effect of thrombolysis, with no evidence of heterogeneity
within the different age strata. This treatment should not
be withheld from older adults, who should be treated
directly, or when there is substantial doubt about the effect
of treatment, these individuals should be asked to partici-
pate in randomized clinical trials.
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DEPRESSIVE SYMPTOMS INCREASE THE RISK OF
MORTALITY IN OLDER MEXICAN
COMMUNITY-DWELLING ADULTS
To the Editor: Depressive symptoms (DSs) are common
in older adults, and their prevalence varies depending on
the instrument used to measure them and the population
studied. DSs represent a major public health concern
because of their association with several adverse health
outcomes such as greater use of medical services, institu-
tionalization, functional and cognitive decline, and
quality of life. Mortality, as an adverse outcome of DS,
has been studied in the context of different diseases, but
epidemiological reports from developing countries in this
respect are scarce, so the main purpose of this 2-year
longitudinal study of 2,615 persons was to determine
whether DSs are an independent predictor of mortality
in a sample of Mexican community-dwelling older adults
without DSs at baseline.
Participants were adults aged 70 and older, all
included in the Mexican Health and Aging Study, who
were evaluated twice (2001 and 2003). DSs were estab-
lished using a modified version of the Center for Epidemio-
logic Studies Depression Scale (CES-D),1 and time of death
was obtained from interviews with the family or proxy
relative at the 2-year follow-up. Cox proportional hazards
models were performed to estimate the risk of death after
adjusting for multiple covariates (age, sex, educational
level, hypertension, diabetes mellitus, stroke, ischemic
cardiopathy, visual impairment, urinary incontinence,
cognitive impairment, smoking, alcohol use, and baseline
activity of daily living (ADL) disability). The interaction
terms between DSs and every one of all covariates were
introduced into the final models, and their statistical signif-
icance was tested using backward selection. All statistical
tests were performed at the .05 level.
RESULTS
Mean age was 76.4 (range: 70–105); 52.9% were female.
Hypertension (42%) was the most frequent chronic
disease. At baseline, 9.3% had ADL disability. DSs were
present in 1,127 (43.1%) individuals. As expected, at base-
line, participants with DSs were older, more likely to be
female, and less educated and reported more chronic
diseases. In addition, participants identified as having DSs
reported more visual and hearing impairment and more
ADL disability, and smoke and consumed alcohol less
frequently than participants without DSs.
The incidence of death was 8.8% (n = 231) at the
2-year follow-up. Participants who had died during fol-
low-up had reported more DSs at baseline than those who
were still alive (11.5% vs 6.8%; P < .001). The unadjusted
Cox proportional hazard model showed that presenting
DSs at baseline almost doubled the risk of death at 2 years
(Table 1). DSs have also been proven to be a statistically
significant predictor of death after adjusting for sociode-
mographic and health covariates because they increase its
risk by 36%.
DISCUSSION
The present study showed that DSs increase mortality risk
regardless of multiple covariates, as has been found in
other rural and urban populations (the majority
Caucasians).2–6 Despite being a common concern in geriat-
rics, in Latin America, this association has been little
explored. In Mexico, depression has been characterized
according to its prevalence and sociodemographic charac-
teristics and its effect on quality of life1,7 but not its
relationship with mortality.
Diverse theories have been proposed to explain how
DSs increase mortality (immunosuppression, hormonal
changes, sympathetic tone increase, diminished vagal tone,
and exacerbation of comorbidities), but the most plausible
is that those with DSs are more likely to develop
unhealthy behavior and habits, have poorer adherence to
treatments, and use fewer healthcare services. Another
hypothesis is that DSs generate more disability, although
the mechanisms by which greater mortality might occur
are unknown.6
Self-reported data and short follow-up could be the
main limitations of the present study, and results must be
interpreted carefully. In spite of the limits, the strength of
this study is its population-based design, and to the
knowledge of the authors, it is among the few in Latin
America that explore this relationship. Given that depres-
sion is often unrecognized and undertreated in older
adults, awareness of the potential for loss of life, as well
as the potential for treatment, may help to improve this
situation. Whatever the mechanism is, the effect of DSs on
mortality seems to be evident, and screening for DS as part
of the routine evaluation of older adults, especially in
primary care, would be of great importance.
Table 1. Cox Proportional Hazard Model of Death
Estimates Over 2 Years of Follow-Up
Adjustment
Hazard Ratio (95%
Confidence Interval) P-Value
Unadjusted 1.74 (1.34–2.25) <.001
Adjusted
Age 1.61 (1.24–2.10) <.001
Sex 1.66 (1.27–2.16) <.001
Education level 1.68 (1.29–2.19) <.001
Hypertension 1.63 (1.24–2.13) <.001
Diabetes mellitus 1.62 (1.23–2.12) .001
Stroke 1.61 (1.23–2.11) .001
Ischemic cardiopathy 1.58 (1.21–2.08) .001
Urinary incontinence 1.45 (1.04–1.99) .004
Visual impairment 1.32 (1.10–1.92) .009
Cognitive impairment 1.50 (1.12–2.02) .007
Smoking 1.50 (1.11–2.01) .007
Alcohol intake 1.47 (1.01–1.97) .01
Disability in activities
of daily living
1.36 (1.01–1.83) .04
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